Aspirin induces IL-4 production: Augmented IL-4 production in aspirin-exacerbated respiratory disease

Experimental and Molecular Medicine

Volumn 48, Issue 1, 2016, Pages

  Kong, Su Kang ^a   Kim, Byung Soo ^a   Uhm, Tae Gi ^a   Chang, Hun Soo ^b   Park, Jong Sook ^b   Park, Sung Woo ^b   Park, Choon Sik ^b   Chung, Il Yup ^a  

^a Hanyang University   (South Korea)

^b Soonchunhyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; INTERLEUKIN 4; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NFAT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADULT; ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASPIRIN TOLERANT ASTHMA; ASTHMA; BIOCHEMISTRY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOKINE PRODUCTION; DNA PROTEIN COMPLEX; DRUG TOLERANCE; FEMALE; GENE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IL 4 GENE; MALE; MIDDLE AGED; MOLECULAR MECHANICS; PATHOGENESIS; PROMOTER REGION; PROTEIN EXPRESSION; UPREGULATION; BREATHING DISORDER; CELL LINE; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; IMMUNOLOGY; INFLAMMATION;

ASPIRIN; CELL LINE; CYCLOOXYGENASE INHIBITORS; HUMANS; INFLAMMATION; INTERLEUKIN-4; RESPIRATION DISORDERS; RNA, MESSENGER; UP-REGULATION;

EID: 85007243630     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2015.96     Document Type: Article

References (62)

1. Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy Asthma Immunol Res 2011; 3: 3-10
2. Farooque SP, Lee TH. Aspirin-sensitive respiratory disease. Annu Rev Physiol 2009; 71: 465-487
3. Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006; 118: 773-786
4. Nasser SM, Pfister R, Christie PE, Sousa AR, Barker J, Schmitz-Schumann M, et al. Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Am J Respir Crit Care Med 1996; 153: 90-96
5. Sousa AR, Pfister R, Christie PE, Lane SJ, Nasser SM, Schmitz-Schumann M, et al. Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma. Thorax 1997; 52: 940-945
6. Varga EM, Jacobson MR, Masuyama K, Rak S, Till SJ, Darby Y, et al. Inflammatory cell populations and cytokine mRNA expression in the masal mucosa in aspirin-sensitive rhinitis. Eur Respir J 1999; 14: 610-615
7. Antczak A, Montuschi P, Kharitonov S, Gorski P, Barnes PJ. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med 2012; 166: 301-306
8. Szczeklik A, Sladek K, Dworski R, Nizankowska E, Soja J, Sheller J, et al. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1996; 154: 1608-1614
9. Cowburn AS, Sladek K, Soja J, Adamek L, Nizankowska E, Szczeklik A, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998; 101: 834-846
10. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med 2007; 357: 1841-1854
11. Laidlaw TM, Kidder MS, Bhattacharyya N, Xing W, Shen S, Milne GL, et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood 2012; 119: 3790-3798
12. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol 1999; 104: 5-13
13. Montuschi P, Peters-Golden ML. Leukotriene modifiers for asthma treatment. Clin Exp Allergy 2010; 40: 1732-1741
14. Szefler SJ, Apter A. Advances in pediatric and adult asthma. J Allergy Clin Imuunol 2005; 115: 470-477
15. Jang AS, Park JS, Lee JH, Park SW, Kim DJ, Uh ST, et al. Asthmatics without rhinitis have more fixed airway obstruction than those with concurrent rhinitis. Allergy Asthma Immunol Res 2010; 2: 108-113
16. Pauls JD, Simon RA, Daffern PJ, Stevenson DD. Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol 2000; 85: 40-45
17. Stevenson DD, Simon RA, Mathison DA, Christiansen SC. Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol 2000; 85: 477-482
18. Berges-Gimeno MP, Simon RA, Stevenson DD. The effect of leukotrienemodifier drugs on aspirin-induced asthma and rhinitis reactions. Clin Exp Allergy 2002; 32: 1491-1496
19. Dahlen SE, Maimstrom K, Nizankowska E, Dahien B, Kuna P, Kowalski M, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 9-14
20. Ragab S, Parikh A, Darby YC, Scadding GK. An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy 2001; 31: 1385-1391
21. Voehringer D, Shinkai K, Locksley RM. Type 2 immunity reflects orchestrated recruitment of cells committed to IL-4 production. Immunity 2004; 20: 267-277
22. Riechelmann H, Deutschle T, Rozsasi A, Keck T, Polzehi D, Burner H. Nasal biomarker profiles in acute and chronic rhinosinusitis. Clin Exp Allergy 2005; 35: 1186-1191
23. Hsieh FH, Lam BK, Penrose JF, Austen KF, Boyce JA. T helper cell type 2 cytokines coordinately regulate immunoglobulin E-dependent cysteinyl leukotriene production by human cord blood-derived mast cells: profound induction of leukotriene C(4) synthase expression by interleukin 4. J Exp Med 2002; 193: 123-133
24. Mellor EA, Austen KF, Boyce JA. Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists. J Exp Med 2002; 195: 583-592
25. Mellor EA, Frank N, Soler D, Hodge MR, Lora JM, Austen KF, et al. Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: functional distinction from CysLT1R. Proc Natl Acad Sci USA 2003; 100: 11589-11593
26. Early SB, Barekzi E, Negri J, Hise K, Borish J, Steinke JW. Concordant modulation of cysteinyl leukotriene receptor expression by IL-4 and IFN-gamma on peripheral immune cells. Am J Respir Cell Mol Biol 2007; 36: 715-720
27. Steinke JW, Payne SC, Borish L. Interleukin-4 in the generation of the AERD phenotype: implications for molecular mechanisms driving therapeutic benefit of aspirin desensitization. J Allergy 2012; 2012: 1-9
28. Schleimer RP, Sterbinsky SA, Kaiser J, Bickel CA, Klunk DA, Tomioka K, et al. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1. J Immunol 1992; 148: 1086-1092
29. Maier E, Duschl A, Horejs-Hoeck J. STAT6-dependent and -independent mechanisms in Th2 polarization. Eur J Immunol 2012; 42: 2827-2833
30. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994; 265: 956-959
31. Perez-G M, Melo M, Keegan AD, Zamorano J. Aspirin and salicylates inhibit the IL-4-and IL-13-induced activation of STAT6. J Immunol 2002; 168: 1428-1434
32. Steinke JW, Culp JA, Kropf E, Borish L. Modulation by aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: possible role in therapeutic benefit associated with aspirin desensitization. J Allergy Clin Immunol 2009; 124: 724-730
33. Cianferoni A, Schroeder JT, Kim J, Schmidt JW, Lichtenstein LM, Georas SN, et al. Selective inhibition of interleukin-4 gene expression in human T cells by aspirin. Blood 2001; 97: 1742-1749
34. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001; 15: 2057-2072
35. Dong Z, Huang C, Brown RE, Ma WY. Inhibition of activator protein 1 activity and neoplastic transformation by aspirin. J Biol Chem 1997; 272: 9962-9970
36. Schwenger P, Skolnik EY, Vilcek J. Inhibition of tumor necrosis factorinduced p42/p44 mitogen-activated protein kinase activation by sodium salicylate. J Biol Chem 1996; 271: 8089-8094
37. White AA, Stevenson DD. Does suppression of IL-4 synthesis by aspirin explain the therapeutic benefit of aspirin desensitization treatment? J Allergy Clin Immunol 2010; 126: 745-746
38. Kim BS, Park SM, Uhm TG, Kang JH, Park JS, Jang AS, et al. Effect of single nucleotide polymorphisms within the interleukin-4 promoter on aspirin intolerance in asthmatics and interleukin-4 promoter activity. Pharmacogenet Genomics 2010; 20: 748-758
39. Kong SK, Kim BS, Uhm TG, Lee W, Lee GR, Park CS, et al. Different GATA factors dictate CCR3 transcription in allergic inflammatory cells in a cell type-specific manner. J Immunol 2013; 190: 5747-5756
40. Uhm TG, Lee SK, Kim BS, Kang JH, Park CS, Rhim TY, et al. CpG methylation at GATA elements in the regulatory region of CCR3 positively correlates with CCR3 transcription. Exp Mol Med 2012; 44: 268-280
41. Burke TF, Casolaro V, Georas SN. Global strategy for asthma management and prevention: GINA executive summary. Biochem Biophys Res Commun 2000; 270: 1016-1023
42. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Fatty acid binding protein 1 is related with development of aspirin-exacerbated respiratory disease. Eur Respir J 2008; 31: 143-178
43. Kim TH, Lee JY, Park JS, Park SW, Jang AS, Lee JY, et al. Fatty acid binding protein 1 is related with development of aspirin-exacerbated respiratory disease. PLoS ONE 2011; 6: e22711
44. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, Swierczynska M, Picado C, Scadding G, et al. EAACI/GA22LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 2007; 62: 1111-1118
45. Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 1994; 91: 2046-2050
46. Huang C, Ma WY, Hanenberger D, Cleary MP, Bowden GT, Dong Z. Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice. J Biol Chem 1997; 272: 26325-26331
47. Pillinger MH, Capodici C, Rosenthal P, Kheterpal N, Hanft S, Philips MR, et al. Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. Proc Natl Acad Sci USA 1998; 95: 14540-14545
48. Li-Weber M, Krammer PH. Regulation of IL4 gene expression by T cells and therapeutic perspectives. Nat Rev Immunol 2003; 3: 534-543
49. Li-Weber M, Giaisi M, Baumann S, Pálfi K, Krammer PH. NF-kappa B synergizes with NF-AT and NF-IL6 in activation of the IL-4 gene in T cells. Eur J Immunol 2004; 34: 1111-1118
50. Hogan PG, Chen L, Nardone J, Rao A. Transcriptional regulation by calcium, calcineurin and NFAT. Genes Dev 2003; 17: 2205-2232
51. Weiss DL, Hural J, Tara D, Timmerman LA, Henkel G, Brown MA. Nuclear factor of activated T cells is associated with a mast cell interleukin 4 transcription complex. Mol Cell Biol 1996; 16: 228-235
52. Gerli R, Paolucci C, Gresele P, Bistoni O, Fiorucci S, Muscat C, et al. Salicylates inhibit adhesion and transmigration of T lymphocytes by preventing integrin activation induced by contact with endothelial cells. Blood 1998; 92: 2389-2398
53. Flescher E, Fossum D, Gray PJ, Fernandes GM, Harper J, Talal N. Aspirin-like drugs prime human T cells. Modulation of intracellular calcium concentrations. J Immunol 1991; 146: 2553-2559
54. Schwenger P, Alpert D, Skolnik EY, Vilcek J. Cell-type-specific activation of c-Jun N-terminal kinase by salicylates. J Cell Physiol 1999; 179: 109-114
55. Mifflin RC, Saada JI, Di Mari JF, Valentich JD, Adegboyega PA, Powell DW. Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol 2004; 65: 470-478
56. Shishodia S, Koul D, Aggarwal BB. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J Immunol 2004; 173: 2011-2022
57. Wang ZL, Fan ZQ, Jiang HD, Qu JM. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling. Carcinogenesis 2013; 34: 638-646
58. Cianferoni A, Massaad M, Feske S, De la Fuente MA, Gallego L, Ramesh N, et al. Defective nuclear translocation of nuclear factor of activated T cells and extracellular signal-regulated kinase underlies deficient IL-2 gene expression in Wiskott-Aldrich syndrome. J Allergy Clin Immunol 2005; 116: 1364-1371
59. Stark LA, Din FV, Zwacka RM, Dunlop MG. Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J 2001; 15: 1273-1275
60. Steinke JW, Negri J, Liu L, Payne SC, Borish L. Aspirin activation of eosinophils and mast cells: Implications in the pathogenesis of aspirinexacerbated respiratory disease. J Immunol 2014; 193: 41-47
61. Steinke JW, Liu L, Huyett P, Negri J, Payne SC, Borish L. Prominent role of IFN-? in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2013; 132: 856-865
62. Schwenger P, Alpert D, Skolnik EY, Vilcek J. Activation of p38 mitogenactivated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IkappaB alpha phosphorylation and degradation. Mol Cell Biol 1998; 18: 78-84